US Supreme Court rules in favor of Sandoz in biosimilars case, enabling earlier access to potentially life-saving medicines

  • US Supreme Court rules that six months’ notice of commercial marketing can be given prior to FDA approval in Sandoz vs. Amgen
  • Justices also provided much needed clarity on the patent litigation process, often referred to as the ‘patent dance’
  • As the first company to gain approval for and launch a biosimilar under the BPCIA’s new regulatory pathway, Sandoz continues to pioneer the path forward for these high-quality, cost-effective medicines in the US

Holzkirchen, 13 June 2017 – Sandoz, a Novartis division, today announced that the Supreme …

/by

US Supreme Court rules in favor of Sandoz in biosimilars case, enabling earlier access to potentially life-saving medicines

  • US Supreme Court rules that six months’ notice of commercial marketing can be given prior to FDA approval in Sandoz vs. Amgen
  • Justices also provided much needed clarity on the patent litigation process, often referred to as the ‘patent dance’
  • As the first company to gain approval for and launch a biosimilar under the BPCIA’s new regulatory pathway, Sandoz continues to pioneer the path forward for these high-quality, cost-effective medicines in the US

Holzkirchen, 13 June 2017 – Sandoz, a Novartis division, today announced that the Supreme …

/by